[1] Delbeke D, Martin WH. PET and PET-CT for evaluation of colorectal carcinoma. Semin Nucl Med, 2004, 34(3):209-223.
[2] Even-Sapir E, Lerman H, Figer A, et al. Role of (18)F-FDG dualhead gamma-camera coincidence imaging in recurrent or metastatic colorectal carcinoma. J Nucl Med, 2002, 43(5):603-609.
[3] Esteves FP, Schuster DM, Halkar RK, et al. Gastrointestinal tract malignancies and positron emission tomography:an overview.Semin Nucl Med, 2006, 36(2):169-181.
[4] Zervos EE, Badgwell BD, Burak WE Jr, et al. Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery,2001, 130(4):636-643.
[5] Flamen P, Hoekstra OS, Homans F, et al. Unexplained rising carcinoembryonic antigen(CEA) in the postoperative surveillance of colorectal cancer:, the utility of positron emission tomography(PET). Eur J Cancer, 2001, 37(7):862-869.
[6] Simo M, Lomena F, Setoain J, et al. FDG-PET improves the management of patients with suspected recurrence of colorectal cancer. Nucl Med Commun, 2002, 23(10):975-982.
[7] Whiterford MH, Whiteford HM, Yee LF, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocareinoma of the colon and rectum. Dis Colon Rectum, 2000,43(6):759-767.
[8] Lonneux M, Reffad AM, Detry R, et al. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.Eur J Nucl Med Mol Imaging, 2002, 29(7):915-921.
[9] Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med, 2000, 41(7):1177-1189.
[10] Khan S, Tan YM, John A, et al. An audit of fusion CT-PET in the management of colorectal liver metastases. Eur J Surg Oncol, 2006,32(5):564-567.
[11] Weng LJ, Akhurst T. Colon cancer metastasis to the adrenal gland demonstrated with FDG PET/CT. Clin Nucl Med, 2004, 29(7)444.
[12] Selzner M, Hany TF, Wildbrett P, et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?. Ann Surg, 2004, 240(6):1027-1034.
[13] Erturk SM, Ichikawa T, Fujii H, et al. PET imaging for evaluation of metastatic colorectal cancer of the liver. Eur J Radiol, 2006, 58(2):229-235.
[14] Tutt AN, Plunker TA, Barrington SF, et al. The role of positron emission tomography in the management of colorectal cancer.Colorectal Dis, 2004, 6(1):2-9.
[15] Desai DE, Zervos EE, Arnold MW, et al. Positron emission tomography affects surgical management in recurrent colorectal cancer patients. Ann Surg Oncol, 2003, 10(1):59-64.
[16] Even-sapirE, Parag Y, Lerman H, et al. Detection of recurrence in patients with rectal cancer:PET/CT after abdominoperineal or anterior resection. Radiology, 2004, 232(3):815-822.
[17] Votrubova J, Belohlavek O, Jaruskova M, et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging, 2006, 33(7):779-784.
[18] Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in the evaluation of cancer:additional value for diagnostic imaging and patient management. J Nucl Med, 2003, 44(8):1200-1209.